OncoCyte Announces Sponsored Symposium at the 2016 American College of Chest Physician’s CHEST 2016 Annual Meeting

ALAMEDA, Calif., Oct. 24, 2016 -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based tests for the detection of cancer, today announced that it will be sponsoring a symposium at the American College of Chest Physician’s 2016 CHEST Annual Meeting, being held in Los Angeles from October 22-26. The symposium is titled Lung Cancer Diagnosis-Challenges and Solutions and is scheduled for Monday, October 24th and will begin at 10:15am PT in the Exhibit Hall (Learning Theater 3).

The symposium will feature a group of clinical experts who will share their perspective on the current challenges in the management of patients with pulmonary nodules, especially those determined to be at intermediate risk for lung cancer.  The speakers will use an interactive case-based approach featuring specific patient profiles to highlight important challenges in the use of existing technologies to establish a definitive diagnosis. The panelists will then discuss the need for new biomarkers, their application, and the level of evidence needed to move these new diagnostic modalities into clinical practice.

The panel speakers are:

• Anil Vachani, MD, MS - Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Veteran’s Administration Medical Center
• Peter Mazzone, MD, MPH - Director of the Lung Cancer Program for the Respiratory Institute at Cleveland Clinic, Director of the Lung Cancer Screening Program
• Nichole T. Tanner, MD, MSCR - Associate Professor of Medicine, Co-Director, Lung Cancer Screening Program, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina

Previously, the Company and The Wistar Institute announced the summary of the analysis of a 610 patient cohort for their lung cancer diagnostic study which will be presented at CHEST.  The study demonstrates the ability of a lung cancer test to distinguish malignant from benign lung growths based on previously identified gene expression signatures, co-developed by Wistar and OncoCyte, under a license from Wistar.  The data will be presented by lead investigator Louise Showe, Ph.D., on Tuesday, October 25^th at 9:00 am.  Dr. Showe is a professor in the Molecular and Cellular Oncogenesis Program and associate director for the Center for Systems and Computational Biology at The Wistar Institute.

About OncoCyte Corporation
OncoCyte is primarily focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for detecting lung, bladder and breast cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein markers that differentially express in specific types of cancer.

Forward Looking Statements
Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. These statements include those pertaining to the implementation and results of our validation study and other studies, commercialization plans, future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for OncoCyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the need and ability to obtain future capital, and maintenance of intellectual property rights, and the need to obtain third party reimbursement for patient’s use of any diagnostic tests we commercialize. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of OncoCyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in OncoCyte’s Securities and Exchange Commission filings. OncoCyte disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:
EVC Group, Inc.
Michael Polyviou
646-445-4800
[email protected]